抗血管生成疗法联合其他药物在晚期非小细胞肺癌中的应用  

Application of anti-angiogenic therapy combined with other drugsin advanced non-small cell lung cancer

作　　者：陆海艳 肖辛瑶 郭舜尧 周易 沈华 LU Haiyan;XIAO Xinyao;GUO Shunyao;ZHOU Yi;SHEN Hua(Department of Oncology,Sir Run Run Hospital,Nanjing Medical University,Nanjing,Jiangsu 211100,China)

机构地区：[1]南京医科大学附属逸夫医院肿瘤科,江苏南京221110

出　　处：《中国临床研究》2025年第3期329-334,共6页Chinese Journal of Clinical Research

基　　金：国家自然科学基金面上项目(82373314)。

摘　　要：血管生成通过向肿瘤输送营养物质和氧气,在大多数实体瘤的发展中起着至关重要的作用,肺癌是一种高度血管化的肿瘤。过去十多年,抑制血管生成已被证实是一种有效且极具前景的联合治疗选择,特别是抗血管内皮生长因子和抗血管内皮生长因子受体疗法,是治疗癌症的常用策略。通过抗血管生成药物诱导的血管正常化效应,将抗血管生成疗法与其他疗法相结合,包括化疗、免疫治疗和靶向治疗,具有良好的疗效。本文就肿瘤血管生成的特征、机制以及抗血管生成联合其他疗法治疗晚期非小细胞肺癌的研究进行综述。Angiogenesis plays a crucial role in the development of most solid tumours by delivering nutrients and oxygen to the tumour,and lung cancer,a highly vascular tumour.Over the past decade or so,inhibition of angiogenesis has been shown to be an effective and highly promising combination therapy option.Particularly,anti-vascular endothelial growth factor(VEGF)and anti-VEGF receptor therapies have been common strategies for cancer treatment.Combining anti-angiogenic therapy with other therapies,including chemotherapy,immunotherapy and targeted therapies,has been shown to be effective through the vascular normalisation effect induced by anti-angiogenic drugs.This article provides a review of the characteristics and mechanisms of tumour angiogenesis and anti-angiogenesis in combination with other therapies for the treatment of advanced non-small cell lung cancer.

关 键 词：抗血管生成 晚期非小细胞肺癌 酪氨酸激酶抑制剂 重组人血管内皮抑制素 免疫治疗 靶向治疗 

分 类 号：R734.2[医药卫生—肿瘤]